To Assess the Pharmacokinetics, Safety, and Tolerability of AZD8233 in Participants With Chronic Kidney Disease (CKD), End Stage Renal Disease (ESRD) and Healthy Participants.

PHASE1TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 10, 2022

Primary Completion Date

November 23, 2022

Study Completion Date

November 23, 2022

Conditions

End Stage Renal Disease

Interventions

DRUG

AZD8233

Participants will receive a single subcutaneous (SC) dose of AZD8233 into the region of the abdomen.

Trial Locations (1)

Research Site, Gdansk